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Abstract
Objectives To compare the clinical and cost effectiveness of total hip
arthroplasty with resurfacing arthroplasty in patients with severe arthritis
of the hip.
Design Single centre, two arm, parallel group, assessor blinded,
randomised controlled trial with 1:1 treatment allocation.
Setting One large teaching hospital in the United Kingdom.
Participants 126 patients older than 18 years with severe arthritis of
the hip joint, suitable for resurfacing arthroplasty of the hip. Patients
were excluded if they were considered to be unable to adhere to trial
procedures or complete questionnaires.
Interventions Total hip arthroplasty (replacement of entire femoral head
and neck); hip resurfacing arthroplasty (replacement of the articular
surface of femoral head only, femoral neck remains intact). Both
procedures replaced the articular surface of the acetabulum.
Main outcome measures Hip function at 12 months after surgery,
assessed using the Oxford hip score and Harris hip score. Secondary
outcomes were quality of life, disability rating, physical activity level,
complications, and cost effectiveness.
Results 60 patients were randomly assigned to hip resurfacing
arthroplasty and 66 to total hip arthroplasty. Intention to treat analysis
showed no evidence for a difference in hip function between treatment
groups at 12 months (t test, P=0.242 and P=0.070 for Oxford hip score
and Harris hip score, respectively); 95% of follow-up data was available
for analysis. Mean Oxford hip score was 40.4 (95% confidence interval
37.9 to 42.9) in the resurfacing group and 38.2 (35.3 to 41.0) in the total
arthroplasty group (estimated treatment effect size 2.23 (−1.52 to 5.98)).
Mean Harris hip score was 88.4 (84.4 to 92.4) in the resurfacing group
and 82.3 (77.2 to 87.5) in the total arthroplasty group (6.04 (−0.51 to
12.58)). Although we saw no evidence of a difference, we cannot
definitively exclude clinically meaningful differences in hip function in
the short term. Overall complication rates did not differ between treatment
groups (P=0.291). However, we saw more wound complications in the
total arthroplasty group (P=0.056) and more thromboembolic events in
the resurfacing group (P=0.049).
Conclusions No evidence of a difference in hip function was seen in
patients with severe arthritis of the hip, one year after receiving a total
hip arthroplasty versus resurfacing arthroplasty. The long term effects
of these interventions remain uncertain.
Trial registration Current Controlled Trials ISRCTN33354155, UKCRN
4093.
Introduction
For patients older than 65 years with severe arthritis of the hip,
several implant designs for total hip arthroplasty (or
replacement) have shown excellent long term results in terms
of both function and value for money.
1 However, in younger
andmoreactivepatients,thesetraditionalimplantshaveafailure
rate of about 50% after 25 years.
2 Modern implant designs for
totalarthroplastycouldimproveontheseresults,
3butthesearch
for new and more durable forms of arthroplasty continues.
In total hip arthroplasty, the patient’s femoral head and neck
are removed and replaced. Resurfacing arthroplasty is an
alternative technique that preserves the neck of the patient’s
femur. The femoral head is then resurfaced with a cap rather
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Research
RESEARCHthanreplaced.Theconceptofresurfacingarthroplastyhasbeen
around for many years, but early implant designs failed owing
to limitations in the materials available and the accuracy of the
production processes.
4 However, improvements in material
scienceandmanufacturingtechnology(inparticular,theability
to manufacture highly congruent metal bearing surfaces) led to
renewed interest in hip resurfacing in the mid-1990s. Modern
metal-on-metal resurfacing arthroplasty became popular in the
early part of the 21st century. Since then, tens of thousands of
youngerpatientsworldwidewithseverearthritisofthehiphave
undergone resurfacing surgery.
5
Resurfacingimplantsaremoreexpensivethantraditional(metal
and plastic) implant designs for total arthroplasty. Resurfacing
also has potential complications compared with total
arthroplasty—most importantly, the risk of fracture of the
femoral neck.
6 However, early clinical results have shown that
in selected patients, 98% of resurfacing implants were still
functioning at five years,
7 which is as good as the revision rates
of any existing implant designs for total arthroplasty.
1
Furthermore,earlyclinicaloutcomessuggestedthatresurfacing
arthroplasty provide more physiological hip movement than
total arthroplasty by preserving the patient’s own proximal
femoral anatomy.
8 9 Other studies
8 10 reported that patients
undergoingresurfacingarthroplastyhadincreasedactivitylevels
compared with those having total hip arthroplasty and were
morelikelytoparticipateinactivitiessuchasrunningandheavy
manual labour. However, these studies were not randomised
clinical trials.
Therefore, we conducted a randomised controlled trial to
compare the clinical effectiveness of total hip arthroplasty with
resurfacing arthroplasty in patients with severe arthritis of the
hip.Wealsocollecteddataforcosteffectiveness(submittedfor
publication).Thenullhypothesisforthistrialwasthatfunctional
hip scores at one year after surgery did not differ between
patients undergoing resurfacing arthroplasty and those
undergoing total hip arthroplasty.
Methods
Thisstudywasasinglecentre,twoarm,parallelgroup,assessor
blinded,randomisedcontrolledtrialwith1:1treatmentallocation
conducted in the United Kingdom. Full details of the protocol
have been described previously,
11 and a summary of the
methodology follows below.
Study population
In this pragmatic trial, participants were eligible if they were
older than 18 years of age, medically fit for an operation, and
suitableforaresurfacingarthroplasty(patientswhoaresuitable
for resurfacing are also suitable for total hip arthroplasty). We
excluded patients from the study if evidence indicated that they
would be unable to adhere to trial procedures or complete
questionnaires. To maintain strict independence between
observed outcome measures, if a recruited patient needed a
contralateralhipreplacementduringthetrialperiod,thesecond
hip was not included in the study.
Recruitment and randomisation of
participants
Patients were recruited between May 2007 and February 2010
from hip replacement clinics at the University Hospitals
Coventry and Warwickshire NHS trust, in Coventry, UK.
Eligible patients gave written informed consent. Patients were
randomly assigned on a 1:1 basis to receive either a total hip
arthroplasty or a resurfacing arthroplasty.
Treatment allocation was determined using a computer
generated, randomised number sequence and stratified by the
supervising orthopaedic surgeon to balance any potential
surgeon effects. After patients consented to participate in the
trial, an independently administered, secure randomisation
service was alerted by telephone of a new enrolment. The
randomisationofficerprovidedthesurgeon’ssecretarywiththe
patient’s treatment allocation, thereby keeping the research
associates, who consented patients and collected outcome data,
blinded to the allocated treatment. The patients were informed,
by letter, of their treatment allocation in the week after
consenting.
Interventions
Thestudytreatmentsweretotalhiparthroplastyandresurfacing
arthroplasty.Beforetheoperation,allpatientsfollowedthesame
preoperativeassessmentprocess.Toensurethatthetrialresults
could be generalised to as wide a group of patients as possible,
eachpatienthadtheallocatedsurgeryaccordingtothepreferred
technique of the operating surgeon. Other perioperative
interventions, such as prophylactic antibiotics and
thromboprophylaxis, were the same for all patients. After the
operation, all patients underwent the same standardised
rehabilitation plan, including range-of-movement exercises
followed by muscle strengthening exercises. Unless the
operating surgeon specifically advised otherwise, all patients
were fully weight bearing immediately.
In a total hip arthroplasty, the femoral head is removed along
with most of the femoral neck. The femoral shaft is exposed to
open up the femoral canal. The femoral component is then
insertedintothecanalandthearticulatingfemoralheadisplaced
onto the neck of the femoral component. The choice of
components(cementedvuncemented)andbearingsurfaceswas
left to the discretion of the operating surgeon, as per their usual
clinical practice.
Inaresurfacingarthroplasty,thearticularsurfacesofthefemoral
head are removed but the neck is left in situ. The femoral
component(cap)isthenimpactedontothepatient’sownfemoral
neck.Allresurfacingarthroplastiesofthehipusemetal-on-metal
bearing surfaces, but the choice of surgical approach, implant
size, and positioning was left to the discretion of the operating
surgeon. In both forms of arthroplasty, the acetabulum is
preparedandtheacetabularcomponentinsertedintothesocket.
Outcome measurements
Primary outcomes
The primary outcome measure was hip function, as assessed by
the Oxford hip score
12 and Harris hip score.
13 The Oxford hip
score is a validated, self administered questionnaire consisting
of 12 items related to daily tasks directly affected by poor hip
function. The Harris hip score is also a questionnaire on hip
functionthatincludesnotonlyitemsreflectingapatient’sability
to perform normal daily activities, but also objective
measurementssuchasrange-of-movementexercises.Therefore,
the questionnaire for Harris hip score was partly completed by
the patient and partly completed by a blinded research
physiotherapist.
Previous work has shown both these hip scores to be reliable
and reproducible measures of hip function after surgery.
12 14 15
However, the self administered Oxford hip score has much
higher follow-up rates than the more widely used Harris hip
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RESEARCHscore.
15 Therefore, to provide the optimal assessment of hip
function after surgery and also to allow dissemination of the
trialresultstoaswideapotentialaudienceaspossible,wechose
to use both hip scores as primary outcome measures. We
collected data for these outcomes at baseline (preoperatively),
andinfollow-upclinicsatsixweeks,threemonths,sixmonths,
and 12 months after surgery. The 12 month follow-up was the
primary endpoint for this trial.
Secondary outcomes
We collected data for four secondary outcome measures at
baseline, and at three, six, and 12 month follow-up:
(1) EuroQol 5D (EQ-5D): a validated quality of life
questionnaire consisting of five questions related to daily
activities scored on a three point ordinal score scale. We
assessed quality of life with both a visual analogue health
scale rating and the combined responses to questions using
published algorithms to obtain values for health related
quality of life
16
(2) Disability rating index: a self administered, 12 item,
visual analogue scale questionnaire assessing the patient’s
own rating of disability
17
(3) Paffenbarger physical activity questionnaire: a
questionnaire that assesses weekly energy expenditure on
leisure and physical activities
18
(4) Any complications recorded during the course of the
trial.
Sample size
To detect a change of 7 points (standard deviation 13) in the
Harrishipscorewithatwosided5%significanceleveland80%
power,basedonapproximatenormalityofthescoredistribution,
we needed 55 patients per group.
15 The change of 7 points is
the lower limit of the range (7 to 10 points) suggested to show
a minimum clinically important difference. Similarly, a change
of 5 points (9) in the Oxford hip score needed 52 patients per
group,againfor80%powerand5%significance.
19Ifweallowed
forananticipateddropoutrateof10%,thetotalsamplesizewas
120 patients. We used a closed testing procedure
(Holm-Bonferroni
20) for the analysis, and made no specific
multiplicity adjustment to the significance level used in the
power analysis.
Statistical analysis
The main analysis assessed differences in primary endpoints at
12monthfollow-upbetweentreatmentgroupsusingindependent
samples and Student t tests on an intention to treat basis. The
overall significance level was set to 5%, with individual test
levels for the primary outcomes adjusted to allow for the
multiple comparisons using the method of Holm-Bonferroni.
20
A prespecified subsidiary analysis used linear regression to
quantify the effects of the treatment groups on each of the
primary outcome measures after adjusting for both patient age
and sex. Estimated treatment effects from these analyses were
presented with 95% confidence intervals. We also analysed
secondary outcome variables using Student t tests and χ
2 tests
as appropriate, and compared total complications rates at 12
months between the two study groups using Fisher’s exact test;
individualtestlevelsfortheseanalysesweresetto5%.Because
the number of missing values at 12 months was small for all
outcome measures, we used a complete case analysis. The
patient was identified as the unit of analysis, but because all
participants in the trial underwent only unilateral procedures,
this unit was synonymous with the hip in the primary analyses.
Results
One hundred and seventy five patients were eligible for
inclusion.
11 Figure 1⇓ shows the flow of these patients through
the trial. Forty nine patients declined to take part; of 47 patients
who expressed a preference, 34 (72%) preferred to receive a
resurfacing arthroplasty. A total of 126 patients consented to
take part in the trial and underwent randomisation: 60 to
resurfacing arthroplasty and 66 to total hip arthroplasty. Four
patients (two in each treatment group) did not undergo hip
arthroplasty surgery during the study period; three patients
withdrew for personal reasons, one patient developed clinical
contraindications to surgery after randomisation. However, we
followed up these patients as per protocol and included their
data in the intention to treat analysis. At the primary endpoint
of 12 months, loss to follow-up was 5% in both groups (fig 1).
Table1⇓summarisesthedemographiccharacteristicsofpatients
at baseline, as well as the patients’ hip function, quality of life,
and disability rating scores before surgery. The two groups of
patients were well balanced in terms of baseline characteristics
and were representative of the wider population of patients
undergoingresurfacingarthroplastyintheUKduringthisperiod
of recruitment. One patient receiving total hip arthroplasty had
a background of Perthes disease. In the resurfacing group, two
patients had a background of developmental dysplasia of the
hip, one had post traumatic arthritis after a previous fracture of
theacetabulum,andonehadahistoryofankylosingspondylitis.
The remaining patients in both groups had osteoarthritis of the
hipastheprimarydiagnosis.Wesawnoevidenceofadifference
in sex distribution (χ
2 test; P=0.984), age (t test; P=0.764), or
hipfunction(ttest;Harrishipscore,P=0.594;Oxfordhipscore,
P=0.959) between patients who were eligible but declined to
takepartandthosepatientswhowereincluded(datanotshown).
Treatment details
Twenty surgeons performed the 122 arthroplasties in this trial.
An orthopaedic consultant was recorded as the lead operating
surgeon in 88 (76%) operations, with the remaining 28 (24%)
being led by senior orthopaedic trainees. The proportion of
consultant versus trainee surgeons was similar in the two
treatmentgroups.Allresurfacingarthroplastieswereperformed
with large diameter metal-on-metal bearings. Of the total hip
arthroplasties, 29 (44%) implants had ceramic-on-ceramic
bearings, 27 (41%) metal-on-metal, three (5%)
ceramic-on-polyethylene,andfive(8%)metal-on-polyethylene.
Three femoral components were cemented and five acetabular
components were cemented; all other components were
implanted uncemented.
Primary outcome
Intentiontotreatanalysisshowedthathipfunctiondidnotdiffer
between treatment groups at 12 months after surgery (t test;
Oxford hip score, P=0.242; Harris hip score, P=0.070; table
2⇓). Temporal trends for the primary outcome measures (fig
2⇓) showed that both functional scores improved from baseline
tosixmonthsaftersurgeryandwerereasonablystablefromthis
time point to the trial endpoint at 12 months. Adjusting for age
and sex in a regression analysis made no qualitative difference
totheconclusions(Oxfordhipscore,P=0.208;Harrishipscore,
P=0.074).Similarly,ananalysisbasedonperprotocoltreatment
allocation also showed no evidence for treatment group
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RESEARCHdifferencesinbothanunadjustedandadjustedanalysis(Oxford
hip score, P=0.574; Harris hip score, P=0.179).
Althoughnoevidenceindicatedsignificanttreatmenteffectson
the primary outcome measures, estimated 95% confidence
intervalsfortreatmentseffectsat12monthsafteroperationwere
relativelywide(Harrishipscore,6.04(−0.51to12.58);Oxford
hip score, 2.23 (−1.52 to 5.98)). Thus, a clinically important
effect cannot be definitively ruled out.
11
Secondary outcomes
We saw no evidence of treatment group effects for any
secondary outcome measures at 12 months. Table 2 shows the
analysis results for the EQ-5D (two sample t test, P=0.173),
EQ-5Dvisualanaloguehealthscale(P=0.580),disabilityrating
index (P=0.111), and results from the Paffenbarger physical
activity questionnaire (P=0.708). Overall complications rates
did not differ between treatment groups (Fisher’s exact test,
P=0.291; table 3⇓). However, we saw more superficial wound
complications in the total arthroplasty group (P=0.056) and
more thromboembolic events in the resurfacing arthroplasty
group (P=0.049).
Discussion
Summary of results
Thisrandomisedclinicaltrialfoundnoevidenceofadifference
in hip function between patients having total hip arthroplasty
versus resurfacing arthroplasty for severe arthritis of the hip
joint. However, we cannot definitively rule out clinically
meaningful differences, and the long term outcome of
resurfacing arthroplasty remains uncertain.
We also saw no evidence of a difference in terms of disability
ratingoractivitylevelsinthefirstyearaftersurgery.Theoverall
rate of complications in the two groups was similar, but we
found evidence of more superficial wound complications in the
total arthroplasty group and more thromboembolic events in
the resurfacing arthroplasty group; however, the number of
events was small. We could not see an obvious reason for the
differenceinthenumberofinfections;ifanything,thesofttissue
dissection (and hence tissue damage) needed for total hip
arthroplastyislessthanthatneededforresurfacingarthroplasty.
The difference in the number of deep vein thromboses could
have been due to the increased rotation of the hip needed to
expose the femoral head in resurfacing arthroplasty. This
movement could have occluded the femoral vein, although we
did not investigate this possibility in this study.
Comparison with other studies
Only a few randomised trials have compared total hip
arthroplasty with the resurfacing technique. The first studies
focused on the technical aspects of the operation, such as the
position of the implants or the amount of bone removed during
the resurfacing procedure.
21 22 More recently, two Canadian
trials compared clinical outcomes for resurfacing arthroplasty
with a specific type of total hip arthroplasty—large diameter,
metal-on-metal total hip arthroplasty.
23 24
Garbuz and colleagues’ study
18 of 107 patients showed no
evidence of a difference in quality of life between the two
treatment groups. However, the authors were concerned about
the high levels of metal debris created by the large metal hip
bearings used in this trial, with the levels of metal ions being
higher in the group receiving total hip arthroplasty than the
group receiving resurfacing arthroplasty. In their trial of 48
patients, Lavigne and colleagues
19 found no evidence of a
difference between treatment groups in their primary outcome
measure, gait speed. However, they too subsequently raised
concerns about the possible adverse effects of large diameter,
metal-on-metal total hip arthroplasty in this group of patients.
25
In both trials, the investigators chose to use the same bearing
surfaces in both treatment groups, that is, large diameter,
metal-on-metalbearings.However,subsequent,widelyreported
concerns regarding the adverse effects of metal debris from
these bearing surfaces have made it difficult to interpret these
trials; particularly because the functional deficits associated
with adverse reactions to metal debris seemed to be greater in
one group (total arthroplasty) than the other (resurfacing
arthroplasty).
26 Furthermore, in the UK, younger patients with
severearthritisofthehipareofferedarangeofbearingsurfaces,
including metal, polyethylene, and ceramic components.
27
Therefore,theCanadiantrialsarenotdirectlyrelevanttoclinical
practice in the UK. We designed the present trial to reflect this
variation in the choice of total arthroplasty across the UK and,
indeed, worldwide.
Strengths and limitations of study
The main strength of this trial is that it was entirely pragmatic,
with a relatively large number of surgeons using different hip
implants and their own preferred surgical technique. Although
we recruited patients from only one centre, the large number of
surgeons involved and the variety of implants used probably
reflects practice in the wider surgical community. Other
strengthsincludedtheuseofvalidated,patientreportedoutcome
tools, which were assessed by researchers who were blinded to
thetypeofhiparthroplasty,andtheveryhighlevelsofcomplete
follow-up data at the primary endpoint (95%).
The key limitation of this trial was that the patients themselves
were not blinded to their type of hip arthroplasty. Patients
undergoingresurfacingarthroplastyintheUKgenerallyreceive
a preoperative information sheet and surgical consent form that
is different from documents given to those undergoing a total
hip arthroplasty. This information details the existing evidence
regarding the different risk-benefit profiles of the two
procedures.Therefore,inourclinicalsettingandafterdiscussion
withourinstitutionalreviewboard,wedidnotconsideritethical
to blind the patients to their treatment allocation within the trial.
Conclusions and policy implications
How do the results of this trial inform the debate about
resurfacing arthroplasty in patients with severe arthritis of the
hip joint? Hip resurfacing has been widely adopted in response
to perceived advantages over total hip arthroplasty. Firstly, the
largediameter,metal-on-metalbearingsaffordedbyresurfacing
couldreducecomplicationsrelatedtowearonmovingsurfaces.
Secondly, preservation of the normal femoral anatomy in
resurfacing would facilitate better hip function and higher
activity levels than with total hip arthroplasty. Thirdly,
preservation of the proximal femoral bone stock would make
revision surgery easier in the future; revision being a distinct
possibility in this younger group of patients who place high
demands on their joint replacement.
In vitro studies have confirmed low rates of wear in large
diameter, metal-on-metal bearing surfaces.
28 However, recent
concerns regarding the effects of metal debris in vivo have
largely superseded these mechanical considerations
26 and even
raised concerns regarding the wider regulation of medical
devices.
29 Arthroplasty registries have indicated that such in
vivo effects could translate into increased revision rates in hip
replacementsthatuselargediameter,metal-on-metalbearings.
30
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RESEARCHThis trial failed to show evidence that resurfacing arthroplasty
provides improved hip function or increased activity levels,
compared with total hip arthroplasty. Patients will be able use
this information when deciding on which type of arthroplasty
to have for their severe arthritis of the hip. However, only long
term studies can determine any advantage with regard to the
need for revision surgery. We will continue to review the
patients in this trial over the coming years.
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RESEARCHWhat is already known on this topic
Total hip replacement is a successful treatment for older patients with severe arthritis of the hip
However, in younger and more active patients, traditional hip replacements might not provide the best function and could wear out
Hip resurfacing is an alternative form of replacement designed specifically to cope with the high functional demands of more active
patients
What this study adds
Despite the theoretical advantages, we found no evidence that hip resurfacing provides better hip function or higher activity levels than
total hip replacement in the first year after surgery
The clinical and cost effectiveness of hip resurfacing in the long term has yet to be established
Tables
Table 1| Baseline characteristics of study participants. Data are mean (standard deviation) unless indicated otherwise
Total hip arthroplasty (n=66) Resurfacing arthroplasty (n=60) Characteristic
30 22 Female sex (n)
56.6 (6.6) 56.3 (7.3) Age (years)
28.7 (4.6) 28.6 (6.3) Body mass index
93 98 Primary diagnosis osteoarthritis (%)
50.1 (13.5) 48.6 (14.2) Harris hip score
19.6 (7.8) 19.1 (8.0) Oxford hip score
0.36 (0.33) 0.33 (0.34) EQ-5D score
57.8 (24.3) 56.7 (22.9) EQ-5D VAS score
57.9 (18.2) 57.0 (16.5) Disability rating index
6.55 (6.72) 8.53 (11.40) Paffenbarger activity (mJ/week)
VAS=visual analogue health scale.
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RESEARCHTable 2| Outcome data for 126 trial participants at 12 months after operation
Effect (95% CI)
Mean (95% CI)
Outcome measure Total hip arthroplasty (n=66) Resurfacing arthroplasty (n=60)
Primary
6.04 (−0.51 to 12.58) 82.3 (77.2 to 87.5) 88.4 (84.4 to 92.4) Harris hip score
2.23 (−1.52 to 5.98) 38.2 (35.3 to 41.0) 40.4 (37.9 to 42.9) Oxford hip score
Secondary
0.077 (−0.034 to 0.188) 0.719 (0.636 to 0.802) 0.796 (0.721 to 0.870) EQ-5D score
2.1 (−5.3 to 9.4) 76.2 (70.8 to 81.5) 78.2 (73.9 to 83.4) EQ-5D VAS scale
−7.1 (−15.8 to 1.6) 34.8 (28.4 to 41.2) 27.7 (21.7 to 33.7) Disability rating index
1.17 (−4.99 to 7.32) 13.85 (10.90 to 17.80) 15.01 (10.15 to 19.87) Paffenbarger activity (mJ/week)
VAS=visual analogue health scale.
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RESEARCHTable 3| Complications by treatment group
P†
Total hip arthroplasty (n=66) Resurfacing arthroplasty (n=60)
Complication Percentage (95% CI) No of events Percentage (95% CI) No of events
0.497 3.0 (0.5 to 11.5) 2* 0.0 (0.0 to 7.5) 0 Deep infection
0.049 0.0 (0.0 to 6.9) 0 6.7 (2.2 to 17.0) 4 Deep vein thrombosis
0.057 13.6 (6.8 to 24.8) 9 3.3 (0.6 to 12.5) 2 Superficial wound complications
1.000 1.5 (0.1 to 9.3) 1 1.7 (0.1 to 10.1) 1 Dislocation
0.747 9.1 (3.7 to 19.4) 6 6.7 (2.2 to 17.0) 4 Other
0.291 27.3 (17.4 to 39.8) 18 18.3 (9.9 to 30.9) 11 Total
*Both patients treated with surgical debridement but neither patient needed revision of the components.
†Fisher’s exact test.
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RESEARCHFigures
Fig 1 Patient flow diagram
Fig 2 Temporal trends in hip function scores after surgery.
31 32 Data are mean (95% confidence interval)
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